Bisphosphonate therapy in pediatric patients

Journal of Diabetes and Metabolic Disorders

Volumn 13, Issue 1, 2014, Pages

  Eghbali Fatourechi, Guiti ^a,b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b Faculty of University College of Omran and Tosseh   (Iran)

Author keywords

Bisphosphonate; Corticoid induced osteoporosis; Nitrogen containing bisphosphonate; Osteogenesis imperfecta; Pediatric bone loss; Pediatric bone malignancy; Pediatric osteoporosis

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; PAMIDRONIC ACID; RISEDRONIC ACID; ZOLEDRONIC ACID;

ADVERSE OUTCOME; ALBRIGHT SYNDROME; ANOREXIA NERVOSA; ANTINEOPLASTIC ACTIVITY; AUTOSOMAL RECESSIVE DISORDER; BONE CANCER; BONE DENSITY; BONE LENGTH; BONE MASS; BONE NECROSIS; BONE REMODELING; BONE TURNOVER; CEREBRAL PALSY; DRUG EFFECT; DRUG MECHANISM; DUCHENNE MUSCULAR DYSTROPHY; EHLERS DANLOS SYNDROME; ENZYME INHIBITION; EWING SARCOMA; EXPERIMENTAL OSTEOPENIA; FIBROUS DYSPLASIA; HUMAN; JUVENILE OSTEOPOROSIS; LANGERHANS CELL HISTIOCYTOSIS; MARFAN SYNDROME; NEUROBLASTOMA; NONHUMAN; OSTEOGENESIS IMPERFECTA; OSTEOLYSIS; OSTEOSARCOMA; PEDIATRICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHYSIOTHERAPY; PSTEOPOROSIS PSEUDOGLIOMA SYNDROME; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SECONDARY AMENORRHEA; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT; WEIGHT CONTROL;

EID: 84988835999     PISSN: None     EISSN: 22516581     Source Type: Journal    
DOI: 10.1186/s40200-014-0109-y     Document Type: Review

References (109)

1. Glorieux FH, Bishop N, Plotkin H, Chabot G, Lanoue G, Travers R: Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 1998, 339:947-952.
2. Rauch F, Cornibert S, Cheung M, Glorieux FH: Long-bone changes after pamidronate discontinuation in children and adolescents with osteogenesis imperfecta. Bone 2007, 40:821-827.
3. Ward L, Tricco AC, Phuong P, Cranney A, Barrowman N, Gaboury I, Rauch F, Tugwell P, Moher D: Bisphosphonate therapy for children and adolescents with secondary osteoporosis. Cochrane Database Syst Rev 2007, 17(4):CD005324.
4. Bachrach LK, Ward LM: Clinical review: bisphosphonate use in childhood osteoporosis. J Clin Endocrinol Metab 2009, 94:400-409.
5. Dwan K, Phillipi CA, Steiner RD, Basel D: Bisphosphonates therapy for osyeogenesis imperfecta. Cochrane Database Syst Rev 2014, 7:CD005088.
6. Nancollas GH, Tang R, Phipps RJ, Henneman Z, Gulde S, Wu W, Mangood A, Russell RGG, Ebetino FH: Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone 2006, 18:617-627.
7. Rogers MJ, Crockett JC, Coxon FP, Mnkknen J: Biochemical and molecular mechanisms of action of bisphosphonates. Bone 2011, 49:34-41.
8. Fisher JE, Rogers MJ, Halasy JM, Luckman SP, Hughes DE, Masarachia PJ, Wesolowski G, Russell RGG, Rodan GA, Reszka AA: Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption and kinase activation in vitro. Proc Natl Acad Sci U S A 1999, 96:133-138.
9. Halasy-Nagy JM, Rodan GA, Reszka AA: Inhibition of bone resorption by alendronate and risedronate does not require osteoclast apoptosis. Bone 2001, 29:553-559.
10. Sutherland KA, Rogers HL, Tosh D, Rogers MJ: RANKL increases the level of Mcl-1 in osteoclasts and reduces bisphosphonate-induced osteoclast apoptosis in vitro. Arthritis Res Ther 2009, 11:R58.
11. Benford HL, Frith JC, Auriola S, Mnkknen J, Rogers MJ: Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs. Mol Pharmacol 1999, 56:131-140.
12. Coxon FP, Thompson K, Roelofs AJ, Ebetino FH, Rogers MJ: Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells. Bone 2008, 42:848-860.
13. Glatt M, Pataki A, Evans GP, Hornby SB, Green JR: Loss of vertebral bone and mechanical strength in estrogen-deficient rats is prevented by long-term administration of zoledronic acid. Osteoporos Int 2004, 15(9):707-715.
14. Weinstein RS, Roberson PK, Manolagas SC: Giant osteoclast formation and long-term oral bisphosphonate therapy. N Engl J Med 2009, 360:53-62.
15. Jain N, Weinstein RS: Giant osteoclasts after long-term bisphosphonate therapy: diagnostic challenges. Nat Rev Rheumatol 2009, 5:341-346.
16. Zhou Z, Guan H, Duan X, Kleinerman ES: Zoledronic acid inhibits primary bone tumor growth in Ewing sarcoma. Cancer 2005, 104(8):1713-1720.
17. Gaspar N, Di Giannatale A, Geoerger B, Redini F, Corradini N: Bone sarcomas: from biology to targeted therapies. Sarcoma Volume 2012, 301975:1-18. 2012.
18. Guan H, Zhou Z, Cao Y, Duan X, Kleinerman EK: VEGF165 promotes the osteolytic bone destruction of Ewing?s sarcoma tumors by up-regulating RANKL. Oncol Res 2009, 18(2-3):117-125.
19. Peng H, Sohara Y, Moats RA, Nelson MD, Groshen SG, Ye W, Reynolds CP, DeClerck YA: The activity of zoledronic acid on neuroblastoma bone metastasis involves inhibition of osteoclasts and tumor cell survival and proliferation. Cancer Res 2007, 67:9346-9355.
20. Di Carlo E, Bocca P, Emionite L, Cilli M, Cipollone G, Morandi F, Raffaghello L, Pistoia V, Prigione I: Mechanisms of the antitumor activity of human V?9Vd2 T cells in combination with zoledronic acid in a preclinical model of neuroblastoma. Moleculartherapy Org 2013, 21(5):1034-1043.
21. Russell HV, Groshen SG, Ara T, DeClerck YA, Hawkins R, Jackson HA, Daldrup-Link HE, Marachelian A, Skerjanec A, Park JR, Katzenstein H, Matthay KK, Blaney SM, Villablanca JG: A phase I study of zoledronic acid and low dose cyclophosphamide in recurrent/refractory neuroblastoma: a new approaches to neuroblastoma therapy (NANT) study. Pediatr Blood Cancer 2011, 57(2):275-282.
22. Rauch F, Travers R, Plotkin H, Glorieux FH: The effects of intravenous pamidronate on the bone tissue of the children and adolescents with osteogenesis imperfecta. J Clin Invest 2002, 110:1293-1299.
23. Rauch F, Plotkin H, Zeitlin L, Glorieux FH: Bone mass, size, and density in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate therapy. J Bone Miner Res 2003, 18(4):610-614.
24. Rauch F, Munns C, Land C, Glorieux FH: Pamidronate in children and adolescents with osteogenesis imperfecta: effect of treatment discontinuation. J Clin Endocrinol Metab 2006, 91:1268-1274.
25. Rauch F, Munns C, Land C, Glorieux FH: Pamidronate in children with osteogenesis imperfecta: histomorphometric effects of treatment discontinuation. J Clinic Endocrinol Metab 2006, 91:1268-1274.
26. Ooi HL, Briody J, McQuade M, Munns CF: Zoledronic acid improves bone mineral density in pediatric spinal cord injury. J Bone Miner Res 2012, 27:1536-1540.
27. Reid IR, Black DM, Eastell R, Bucci-Rechtweg C, Su G, Hue TF, Mesenbrink P, Lyles KW, Boonen S: Reduction in the risk of clinical fractures after a single dose of zolendronic 5 milligrams. J Clin EndocrinolMetab 2013, 98:557-563.
28. Ward LM, Rauch M, Whyte MP, D Astous J, Gates PE, Grogan D, Lester EL, McCall RE, Pressly TA, Sanders JO, Smith PA, Steiner RD, Sullivan E, Tyerman G, Smith-Wright DL, Verbruggen N, Heyden N, Lombardi A, Glorieux FH: Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo-controlled study. J Clin Endocrinol Metab 2011, 96:355-364.
29. Munns CF, Rajab MH, Hong J, Briody J, Hgler W, McQuad M, Little DG, Codwell CT: Acute phase response and mineral status following low dose intravenous zoledronic acid in children. Bone 2007, 41:366-370.
30. Morimoto A, Shioda Y, Imamura T, Kanegane H, Sato T, Kudo K, Nakagawa S, Nakadate H, Tauchi H, Hama A, Yasui M, Nagatoshi Y, Kinoshita A, Miyaji R, Anan T, Yabe M, Kamizono J: Nationwide survey of bisphosphonate therapy for children with reactivated langerhans cell histiocytosis in Japan. Pediatr Blood Cancer 2011, 56:110-115.
31. Rizzoli R, Burlet N, Cahall D, Delmas PD, Eriksen EF, Felsenberg D, Grbic J, Jontell M, Landesberg R, Laslop A, Wollenhaupt M, Papapoulos S, Sezer O, Sprafka M, Reginster JY: Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. Bone 2008, 42:841-847.
32. Munns CF, Rauch F, Mier RJ, Glorieux FH: Respiratory distress with pamidronate treatment in infants with severe osteogenesis imperfecta. Bone 2004, 35:231-234.
33. Munns CF, Rauch F, Ward L, Glorieux FH: Maternal and fetal outcome after long-term pamidronate treatment before conception: a report of two cases. J Bone Miner Res 2004, 19:1742-1745.
34. Miller KK, Grieco KA, Mulder J, Grinspoon S, Mickley D, Yehezkel R, Hertzog DB, Klibanski A: Effects of risedronate on bone density in anorexia nervosa. J Clinic Endocrinol Metab 2004, 89(8):3903-3906.
35. Papapoulos SE, Cremers CL: Prolonged bisphosphonate release after treatment in children. N Engl J Med 2007, 356:1075-1076.
36. Patlas N, Golomb G, Yaffe P, Pinto T, Breuer E, Ornoy A: Transplacental effects of bisphosphonates on fetal skeletal ossification and mineralization in rats. Teratology 1999, 60:68-73.
37. Whyte MP, Wenkert D, Clements KL, McAlister WH, Mumm S: Bisphosphonate-induced osteopetrosis. N Eng J Med 2003, 349:457-463.
38. Battaglia S, Dumoucel S, Chesneau J, Heymann MF: Impact of oncopediatric dosing regimen of zoledronic acid on bone growth: preclinical studies and case report of an osteosarcoma pediatric patient. J Bone Miner Res 2011, 26(10):2439-2451.
39. Mayranpaa MK, Tamminen IS, Kroger H, Makitie O: Bone biopsy findings and correlation with clinical, radiological, and biochemical parameters in children with fractures. J Bone Miner Res 2011, 26:1748-1758.
40. Bianchi ML: Osteoporosis in children and adolescents. Bone 2007, 41:486-495. 2011.
41. Goulding A, Grant AM, Williams SM: Bone and body composition of children and adolescents with repeated forearm fractures. J Bone Miner Res 2005, 20:2090-2096.
42. Farr JN, Amin S, Melton LJ III, Kirmani S, McCready LK, Atkinson E, Mller R, Sundeep K: Bone strength and structural deficits in children and adolescents with a distal forearm fracture due to mild trauma. J Bone Miner Res 2013, doi:10.1002/jbmr.2071.
43. Bishop N, Braillon P, Burnham J, Cimaz R, Davies J, Fewtrell M, Hogler W, Kennedy K, Makitie O, Mughal Z, Shaw N, Vogiatzi M, Ward K, Bianchi ML: Dual-energy X-ray absorptiometry assessment in children and adolescents with diseases that may affect the skeleton: the 2007 ISCD pediatric official positions. J Clin Densitom 2007, 11:29-42.
44. Rauch F, Lalic L, Roughley P, Glorieux FH: Relationship between genotype and skeletal phenotype in children and adolescents with osteogenesis imperfect. J Bone Miner Res 2010, 25:1367-1374.
45. Glorieux FH, Moffat P: Osteogenesis imperfecta, an ever-expanding conundrum. J Bone Miner Res 2013, 28(7):1519-1522.
46. Sillence DO, Senn A, Danks DM: Genetic heterogeneity in osteogenesis imperfecta. J Medic Genet 1979, 16:101-116.
47. Van Dijk FS, Sillence DO: Osteogenesis imperfecta: clinical diagnosis, nomenclature and severity assessment. Am J Med Genet A 2014, 8(10):36545.
48. Cho TJ, Lee KE, Lee SK, Song SJ, Kim KJ, Jeon D, Lee G, Kim HN, Lee HR, Eom HH, Lee ZH, Kim OH, Park WY, Park SS, Ikegava S, Yoo WJ, Choi IH, Kim JW: A single recurrent mutation in the 5'-UTR of IFITM5 causes osteogenesis imperfecta type V. Am J Hum Genet 2012, 91(2):343-348.
49. Glorieux FH, Ward LM, Rauch F, Lalic L, Roughley PJ, Travers R: Osteogenesis imperfecta type VI: a form of brittle bone disease with a mineralization defect. J Bone Miner Res 2002, 17(1):30-38.
50. Ward LM, Rauch F, Travers R, Chabot G, Azouz EM, Lalic L, Roughley PJ, Glorieux FH: Osteogenesis imperfecta type VII: an autosomal recessive form of brittle bone disease. Bone 2002, 31(1):12-18.
51. Rauch F, Glorieux FH: Osteogenesis imperfecta. Lancet 2004, 363:1377-1385.
52. Kelley BP, Malfait F, Bonafe L, Baldridge D, Homan E, Symoens S, Willaert A, Elcioglu N, Van Maldergem L, Velleren-Dumoulin C, Gillerot Y, Napierala D, Krakow D, Beighton P, Superti-Furga A, De Paepe A, Brendan L: Mutations in FKBP10 cause recessive osteogenesis imperfecta and bruck syndrome. J Bone Min Res 2011, 26(3):666-672.
53. Malfait F, Hakim AJ, De Paepe A, Grahame R: The genetic basis of joint hypermobility syndromes. Rheumatology 2006, 45:502-507.
54. Beighton P, De Paepe A, Steinmann B, Tsipouras P, Wenstrup RJ: Ehlers-Danlos syndromes: revised nosology, Villefranche, 1997. Ehlers-Danlos National Foundation (USA) and Support Group (UK). Am J Med Genet 1998, 77:31-37.
55. Bank RA, Robins SP, Wijmenga C, Breslau-Siderius LJ, Bardoel AF, van der Sluijs HA, Pruijs HE, Tekoppele JM: Defective collagen crosslinking in bone, but not in ligament or cartilage, in bruck syndrome: indications for a bone-specific telopeptide lysyl hydroxylaseon chromosome 17. Proc Natl Acad Sci U S A 1999, 96:1054-1058.
56. Milewicz DM: Molecular genetics of Marfan syndrome and Ehlers-Danlos type IV. Curr Opin Cardiol 1998, 13(3):198-204.
57. Robinson PN, Maurice G: The molecular Genetic of Marfan syndrome and related microfibrillopathies. J Med Genet 2000, 37:9-25.
58. Narumi S, Numakura C, Shiihara T, Seiwa C: Various types of LRP5 mutations in four patients with osteoporosis-pseudoglioma syndrome: identification of a 7.2-kb microdeletion using oligonucleotide tiling microarray. Am J Med Gen A 2009, 152A(1):133-140.
59. Sbrocchi AM, Rauch F, Jacob P, McCormick A, McMillan HJ, Matzinger MA, Ward LM: The use of intravenous bisphosphonate therapy to treat vertebral fractures due to osteoporosis among boys with duchenne muscular dystrophy. Osteoporosis Int 2012, 23:2703-2711.
60. Gordon KE, Dooley JM, Sheppard KM, MacSween J, Esser MJ: Impact of bisphosphonates on survival for patients with duchenne muscular dystrophy. Pediatrics 2011, 127:e.353-e.358.
61. Liu JH, Bill AH: Stress-associated or functional hypothalamic amenorrhea in the adolescent. Ann N Y Acad Sci 2008, 1135:179-184.
62. Gordon CM: Functional hypothalamic amenorrhea. N Engl J Med 2010, 363:365-371.
63. Meczekalski B, Podfigurna-Stopa A: Functional hypothalamic amenorrhea: current view on neuroendocrine aberrations. Gynecolo Endocrinol 2008, 24:4-11.
64. Nattiv A, Loucks AB, Manore MM, Sanborn CF, Sundgot-Borgen J, Warren MP: American college of sports medicine position stand: the female athlete triad. Med Sci Sports Exerc 2007, 39:1867-1882.
65. De Souza MJ, Nattiv A, Joy E, Misra M, Williams NI, Mallinson RJ, Gibbs JC, Olmsted M, Goolsby M, Matheson G: Female athlete S coalition consensus statement on treatment and return to play of the female athlete triad: 1st international conference held in San Francisco, California, May 2012 and 2nd international conference held in Indianapolis, Indiana, May Br J Sports Med 2014, 48:289.
66. Hoek HW, van Hoeken D: Review of the prevalence and incidence of eating disorders. Int J Eat Disord 2003, 34:383-396.
67. Yager J, Anderson AE: Anorexie nervosa. New Engl J Med 2005, 353:1481-1488.
68. Canalis E, Mazziotti G, Giustina A, Bilzekian JP: Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int 2007, 18:1319-1328.
69. Van Staa TP, Cooper HG, Leufkens HG, Bishop N: Children and the risk of fractures caused by oral corticosteroids. J Bone Miner Res 2003, 18:913-918.
70. Agastiniotis M, Modell B: Global epidemiology of hemoglobin disorders. Ann N Y Acad Sci 1998, 850:251-259.
71. Rund D, Rachmilewitz E: ß thalassemia. N Engl J Med 2005, 353:1135-1146.
72. Morabito N, Gaudio A, Lasco A, Atteritano M, Pizzoleo MA, Cincotta M, La Rosa M, Guarino R, Meo A, Frisina N: Osteoprotegerin and RANKL in the pathogenesis of thalassemia-induced osteoporosis: new pieces of the puzzle. J Bone Min Res 2004, 19(5):722-727.
73. Vogiatzi M, Mackin E, Fung EB, Cheung AM, Vichinsky E, Olivieri N, Kirby M, Kwiatkowski JL, Cunningham M, Holm IA, Lane J, Schneider R, Fleisher M, Grady RW, Peterson CC, Giardina PJ: Bone disease in thalassemia: a frequent and still unresolved problem. J Bone Min Res 2009, 24:543-557.
74. Fung EB, Vichinsky EP, Kwiatkowski JL, Huang J, Bachrach LK, Sawyer AJ, Zemel BS: Characterization of low bone mass in young patients with thalassemia by DXA, pQCT and markers of bone turnover. Bone 2011, 48(6):1305-1312.
75. August KJ, Dalton A, Katzenstein HM, George B, Olson TA, Wasilewski-Masker K, Rapkin LB: The use of zoledronic acid in pediatric cancer patients. Pediatr Blood Cancer 2011, 56:610-614.
76. Taylor R, Knowles HJ, Athanasou NA: Ewing sarcoma cells express RANKL and support osteoclastogenesis. J Pathol 2011, 225(2):195-202. doi:10.1002/path.2869.
77. Chad KE, McKay HA, Zello GA, Bailey DA, Faulkner RA, Snyder RE: The effect of a weight-bearing physical activity program on bone mineral content and estimated volumetric density in children with spastic cerebral palsy. J Pediatr 1999, 135:115-117.
78. De Sanctis V: Growth and puberty and its management in thalassemia. Horm Res 2002, 58(Suppl;1):72-79.
79. Misra M, Pacaud D, Petryk A, Collett-Solberg PF, Kappy M: Vitamin D deficiency in children and its management: review of current knowledge and recommendations. Pediatrics 2008, 122:398-417.
80. Edouard T, Glorieux FH, Rauch F: Predictors and correlates of vitamin D Status in children and adolescents with osteogenesis imperfecta. J Clin Endocrinol Metab 2011, 96:3193-3198.
81. Tashjian AH, Gagel RF: Teriparatide [Human PTH(1-34)]: 2.5 years of experience on the use and safety of the drug for the treatment of osteoporosis. J Bone Miner Res 2006, 21:354-365.
82. Teitelbaum SL, Ross FP: Genetic regulation of osteoclast development and function. Nat Rev Genet 2003, 4:638-649.
83. Lamoureux F, Richard P, Wittrant Y, Battaglia S, Pilet P, Trichet V, Blanchard F, Gouin F, Pitar B, Heymann D, Redini F: Therapeutic relevance of osteoprotegerin gene-therapy in osteosarcoma: blockade of vicious cycle between tumor cell proliferation and bone resorption. Cancer Res 2007, 67(15):7308-73-18.
84. Miller KK, Meenaghan E, Lawson EA, Misra M, Gleysteen S, Schoenfeld D, Hertzog D, Klibanski A: Effects of risedronate and low-dose transdermal testosterone on bone mineral density in women with anorexia nervosa: a randomized, placebo-controlled study. J Clin Endocrinol Metab 2011, 96(7):2081-2088.
85. Plotkin H, Rauch F, Bishop NJ, Monpetit K, Ruck-Gibis J, Travers R, Glorieux FH: Pamidronate treatment of severe osteogenesis imperfect in children under years of age. J Clin Endocrinol Metab 2000, 85:1846-1850.
86. Letocha AD, Cintas HL, Troendle JF, Reynolds JC, Cann EC, Chernoff EJ, Hill SC, Gerber LH, Marini JC: Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement. J Bone Miner Res 2005, 20:977-986.
87. Dominguez-Bartmess SN, Tandberg D, Cheema AM, Szalay EA: Efficacy of Alendronate in the treatment of low bone density in the pediatric and young adult population. J Bone Joint Surg Am 2012, 94(10):e62(1-6).
88. Bishop N, Adami S, Ahmed SF, Anton J, Arundel P, Burren CP, Devogelaer JP, Hangartner T, Hossozu E, Lane JM, Lorenc R, Mkitie O, Munns CF, Paredes A, Pavlov H, Plotkin H, Raggio CL, Reyes ML, Schoenau E, Semler O, Sillence DO, Steiner RD: Risedronate in children with osteogenesis imperfecta: a randomized, double-blind, placebo-controlled trial. Lancet 2013, 382:1424-1432.
89. De Nijs RNJ, Jacobs JWG, Lems WF, Laan RFJ, Algra A, Huisman AM, Buskens E, de Laet CED, Oostveen ACM, Geusens PPMM, Bruyn GAW, Dijkmans BAC, Bijlsma JWJ: Alendronate or alfacalcidol in glucocorticoide-induced osteoporosis. N Engl J Med 2006, 355:675-684.
90. Noguera A, Ros JB, Pavia C, Alcover E, Valls C, Villaronga M, Gonzlez E: Bisphosphonates, a new treatment for glucocorticoid-induced osteoporosis in children. J Pediat Endocrinol Metab 2003, 16:529-536.
91. Rudge S, Hailwood S, Horne A, Lucas J, Wu F, Cundy T: Effects of once-weekly oral alendronate on bone in children on glucocorticoid treatment. Rheumatology 2005, 44:813-818.
92. Kubista B, Trieb K, Sevelda F, Toma C: Anticancer effects of zoledronic acid against human osteosarcoma cells. J Orthop Res 2006, 24(6):1145-1152.
93. Odri GA, Dumoucel S, Picarda G, Battaglia S: Zoledronic acid as a new adjuvant therapeutic strategy for Ewing?s sarcoma patients. Cancer Res 2010, 70(19):7610-7619.
94. Odri G, Kim PP, Lamoureux F, Charrier C, Battaglia S, Amiaud J, Heymann D, Guin F, Redini F: Zoledronic acid inhibits pulmonary metastasis dissemination in a preclinical model of Ewing?s sarcoma via inhibition of cell migration. BMC Cancer 2014, 14:169.
95. Anninga JK, Cleton-Jansen AM, Hassan B, Amary MF, Baumhoer D, Blay JY, Brugieres L, Ferrari S, Jrgens H, Kempf-Bielack B, Kovar H, Myklebost O, Nathrath M, Picci P, Riegman P, Schilham MW, Soliman R, Stark DP, Strauss S, Sydes M, Tarpey P, Thomas D,Whelan J, WilhelmM, ZamzamM, Gelderblom H, Bielack SS: Workshop report on the 2nd Joint ENCCA/EuroSARC European bone sarcoma network meeting: integration of clinical trials with tumour biology. Clin Sarcoma Res 2014, 4:4 [http://www.clinicalsarcomaresearch.com/ content/4/1/4]
96. Leblicq C, Laverdire C, Dcarie JC, Delisle JF, Isler MH, Moghrabi A, Chabot G, Alos N: Effectiveness of pamidronate as treatment of symptomatic osteonecrosis occurring in children treated for acute lymphoblastic leukemia. Pediatr Blood Cancer 2013, 60(5):741-747.
97. Padhye B, Dalla-Pozza L, Little DG, Munns CF: Use of zolendronic acid for treatment of chemotherapy-related osteonecrosis in children and adolescents: a retrospective analysis. Pediatr Blood Cancer 2013, 60(9):1539-1545.
98. Golden NH, Iglesias EA, Jacobson MS, Carey D, Schebendach J, Hertz S, Shenker IR: Alendronate for the treatment of osteopenia in anorexia nervosa: a randomized, double-blind, placebo-controlled trial. J Clin Endocrinol Metab 2005, 90:3179-3185.
99. Golden NH, Lanzkowsky L, Schebendach J, Palestro CJ, Jacobson MS, Shenker IR: The effect of estrogen-progestin treatment on bone mineral density in anorexia nervosa. J Pediatr Adolesc Gynecol 2002, 15(3):135-143.
100. Grinspoon S, Thomas L, Miller K, Herzog D, Klibanski A: Effect of recombinant human IGF-I and oral contraceptive administration on bone density in anorexia nervosa. J Clin Endocrinol Metab 2002, 87:2883-2891.
101. Misra M, Klibanski A: Bone metabolism in adolescent with anorexia nervosa. J Endocrinol Invest 2011, 34(4):324-332.
102. Misra M, Klibanski A: Endocrine consequences of anorexia nervosa. Lancet Diabetes Endocrinol 2014, 2(7):581-592.
103. Chapurlat RD, Delmas PD, Liens D, Meunier PJ: Long-term effects of intravenous pamidronate in fibrous dysplasia of bone. J Bone Miner Res 1997, 12:1746-1752.
104. Chapurlat RD, Hugueny P, Delmas PD, Meunier PJ: Treatment of fibrous dysplasia of bone with intravenous pamidronate: long-term effectiveness and evaluation of predictors of response to treatment. Bone 2004, 35:235-242 y.
105. Henderson RC, Lark RK, Kecskemethy HH, Miller F, Harcke HT, Bachrach SJ: Bisphosphonates to treat osteopenia in children with quadriplegic cerebral palsy: a randomized, placebo-controlled clinical trial. J Pediatr 2002, 141:644-651.
106. Fehlings D, Switzer L, Agarwal P, Wong C, Sochett E, Stevenson R, Sonnenberg L, Smile S, Young E, Huber J, Milo-Manson G, Kuwaik GA, Gaebler D: Informing evidence-based clinical practice guidelines for children with cerebral palsy at risk of osteoporosis: a systematic review. Dev Med Child Neurol 2012, 54:106-116. 2012.
107. Bachrach SJ, Kecskemethy HH, Hrcke HT, Hossain J: Decreased fracture incidence after 1 year of pamidronate treatment in children with spastic quadriplegic cerebral palsy. Dev Med Child Neurol 2010, 52(9):837-842. 2010.
108. Bryson JE, Gourlay ML: Bisphosphonate use in acute and chronic spinal cord injury: a systematic review. J Spinal Cord Med 2009, 32:215-225.
109. Giusti A: Bisphosphonates in the management of thalassemia-associated osteoporosis: a systematic review of randomized controlled trials. J Bone Miner Metab published online April 2014 [Epub ahead of print].